ZYNE News

Biotech companies lead a weak week in IPOs. So far this year, 127 companies have come public, and the average first-day pop has been about 16%. In the past two weeks, 8 of 12 IPOs ended their first day down or flat. The downward trend accelerated this week with an average first-day return...read more

Zynerba Pharmaceuticals, a preclinical biotech developing transdermal cannabinoid-based therapies, raised $42 million by offering 3 million shares at $14, the midpoint of the $13-$15 range. Perceptive Advisors, a biotech-focused hedge fund, has indicated an interest in purchasing up to $12 million on the offering (29% of the deal). At its offer price, Zynerba commands a...read more

August 2015 kicks off with ten IPOs on the calendar for this week - more IPOs than all of August 2014 - after a slower than average July. Based on the number of ...read more

Zynerba Pharmaceuticals, a preclinical biotech developing cannabinoid-based therapies for osteoarthritis and epilepsy, announced terms for its IPO on Thursday. The Devon, PA-based company plans to raise $42 million by offering 3.0 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $128 million. ...read more